Phase 3 trial reports safety outcomes of fremanezumab in adolescents with episodic migraine, suggesting effective migraine prevention.
Background/Purpose: There are limited well-tolerated migraine preventives approved for children and adolescents. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway, such as fremanezumab, are approved for preventive migraine treatment in adults. There are currently limited data on the safety of these mAbs in children and adolescents. This study (NCT04458857) aimed to evaluate the efficacy, safety, and tolerability of fremanezumab in children and adolescents with episodic migraine (EM). Here, we present the safety outcomes.
No takes yet. Share an insight, caveat, or question.
Hershey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: